Discounted Cash Flow (DCF) Analysis Levered
Pharmasimple SA (ALPHS.PA)
0.0129 €
0.00 (0.00%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected |
| Revenue | 19.17 | 17.13 | 28.65 | 46.47 | 64.88 | 90.57 | 126.45 | 176.53 | 246.44 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | |||||||||
| Operating Cash Flow | -2.90 | -2.59 | -4.33 | -7.02 | -9.81 | -13.69 | -19.11 | -26.68 | -37.25 |
| Operating Cash Flow (%) | |||||||||
| Capital Expenditure | - | - | - | - | - | - | - | - | - |
| Capital Expenditure (%) | |||||||||
| Free Cash Flow | - | -2.59 | -4.33 | -7.02 | -9.81 | -13.69 | -19.11 | -26.68 | -37.25 |
Weighted Average Cost Of Capital
| Share price | $ 0.0,129 |
|---|---|
| Beta | 1.023 |
| Diluted Shares Outstanding | - |
| Cost of Debt | |
| Tax Rate | -35.13 |
| After-tax Cost of Debt | 1.32% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 9.264 |
| Total Debt | 7.89 |
| Total Equity | - |
| Total Capital | 7.89 |
| Debt Weighting | 100.00 |
| Equity Weighting | 0.00 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected |
| Revenue | 19.17 | 17.13 | 28.65 | 46.47 | 64.88 | 90.57 | 126.45 | 176.53 | 246.44 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.90 | -2.59 | -4.33 | -7.02 | -9.81 | -13.69 | -19.11 | -26.68 | -37.25 |
| Capital Expenditure | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | -2.59 | -4.33 | -7.02 | -9.81 | -13.69 | -19.11 | -26.68 | -37.25 |
| WACC | |||||||||
| PV LFCF | -9.81 | -13.51 | -18.62 | -25.65 | -35.34 | ||||
| SUM PV LFCF | -101.58 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 1.32 |
| Free cash flow (t + 1) | -37.99 |
| Terminal Value | 5,586.88 |
| Present Value of Terminal Value | 5,232.31 |
Intrinsic Value
| Enterprise Value | 5,130.73 |
|---|---|
| Net Debt | 7.93 |
| Equity Value | 5,122.80 |
| Shares Outstanding | - |
| Equity Value Per Share | Infinity |